The Role of Focal Therapy and Active Surveillance for Small Renal Mass Therapy

Abstract

Small and low-grade renal cell carcinomas have little potential for metastasis and disease-related mortality. As a consequence, the main problem remains the use of appropriately tailored treatment for each individual patient. Surgery still remains the gold standard, but many clinicians are questioning this approach and present the advantages of focal therapy. The choice of treatment regimen remains a matter of debate. This article summarizes the current treatment options in the management of small renal masses.

Surgical Approach in Metastatic Renal Cell Carcinoma: A Literature Review

“…Five year OS for localized RCC exceeds 90% [ 5 ] compared to 20% for the metastatic type [ 6 ]. Surgery remains the standard of treatment for all stages [ 7 ]. Within it, we distinguish between complete (cMS) and incomplete (icMS) metastatectomy, and partial (PN) or complete (RN) nephrectomy.…”

Advances in the Treatment of Kidney and Upper Urinary Tract Cancers

“…This Special Issue aims to cover novel approaches in renal and urothelial cancers. We collected papers focused on novel approaches to urothelial cancers involving upper urinary tract and renal cancers that undertook original research focused on pre-clinical studies and biomarkers [ 9 , 10 , 11 , 12 ], prognostic models [ 13 , 14 , 15 ], the specific population of metastatic patients [ 16 ], and, finally, two narrative reviews [ 17 , 18 ].…”

“…The recent review by Matuszczak et al [ 17 ] summarized the current treatment options in the management of small renal masses. Briefly, despite the advances in focal methods that have been made in recent years, the NCCN guidelines recommend PN as the preferred method in patients with stage T1a tumors.…”